MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
3.430
-0.140
-3.92%
Pre Market: 3.436 +0.006 +0.16% 05:37 05/29 EDT
OPEN
3.570
PREV CLOSE
3.570
HIGH
3.577
LOW
3.360
VOLUME
426
TURNOVER
--
52 WEEK HIGH
4.537
52 WEEK LOW
1.565
MARKET CAP
526.37M
P/E (TTM)
-2.8060
1D
5D
1M
3M
1Y
5Y
1D
Editas Medicine updates presentation time for Jefferies Global Healthcare Conference
PUBT · 20h ago
Editas Medicine: Resetting Pipeline Just To Be Second To Market Again
Seeking Alpha · 1d ago
Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX
NASDAQ · 1d ago
Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI
TipRanks · 1d ago
TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’
TipRanks · 2d ago
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Benzinga · 2d ago
Editas Medicine Raises Capital Through Public Equity Offering
TipRanks · 2d ago
Editas Medicine Prices Up To $319.4 Million Public Offering
NASDAQ · 2d ago
More
About EDIT
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.